within Pharmacolibrary.Drugs.ATC.R;

model R03DX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.004833333333333333,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.00309,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0028333333333333335,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Benralizumab is a humanized monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα) on eosinophils, leading to their depletion. It is used for the treatment of severe eosinophilic asthma and is approved for this indication in many countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adults and adolescents (12–75 years) with severe eosinophilic asthma following subcutaneous administration.</p><h4>References</h4><ol><li><p>Emson, C, et al., &amp; Bachert, C (2024). Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial. <i>British journal of clinical pharmacology</i> 90(8) 1952–1963. DOI:<a href=&quot;https://doi.org/10.1111/bcp.16087&quot;>10.1111/bcp.16087</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38715387/&quot;>https://pubmed.ncbi.nlm.nih.gov/38715387</a></p></li><li><p>Cheung, TT, et al., &amp; Zheng, W (2023). Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants. <i>Drug design, development and therapy</i> 17 209–218. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S392155&quot;>10.2147/DDDT.S392155</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36726737/&quot;>https://pubmed.ncbi.nlm.nih.gov/36726737</a></p></li><li><p>Wang, B, et al., &amp; Roskos, LK (2017). Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 6(4) 249–257. DOI:<a href=&quot;https://doi.org/10.1002/psp4.12160&quot;>10.1002/psp4.12160</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28109128/&quot;>https://pubmed.ncbi.nlm.nih.gov/28109128</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03DX10;
